Cardiovascular

Educational resources

Jardiance SMC guidance card index image

Empagliflozin (Jardiance®) 10mg film-coated tablets SMC2396

Promotional material from the Boehringer Ingelheim and Lilly Alliance

The production of this Guidelines  summary card has been commissioned by the Boehringer Ingelheim and Lilly Alliance.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105816 October 2021

website index image

Updates in best practice management of venous thromboembolism

Commissioned by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance

These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100782 | Date of preparation: September 2021

Index image2

Modern management of stroke prevention in non-valvular atrial fibrillation

Commissioned by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance

These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100689 | Date of preparation: August 2021

Calculating renal function animation

Calculating renal function in patients with atrial fibrillation

Developed and funded by the Bristol Myers Squibb/Pfizer Alliance

This animation has been developed and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals.

432-GB-2100230  June 2021

Video index image

The holistic management of patients requiring anticoagulation

Commissioned by Bayer plc

This video has been commissioned and funded by Bayer plc and developed in partnership with Guidelines
View Xarelto(rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-1924 January 2021